Home » Stocks » LYRA

Lyra Therapeutics, Inc. (LYRA)

Stock Price: $10.47 USD -0.36 (-3.32%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
After-hours: $10.41 -0.06 (-0.57%) Apr 16, 4:29 PM
Market Cap 140.39M
Revenue (ttm) n/a
Net Income (ttm) -22.13M
Shares Out 12.96M
EPS (ttm) -2.59
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $10.47
Previous Close $10.83
Change ($) -0.36
Change (%) -3.32%
Day's Open 10.90
Day's Range 10.32 - 11.00
Day's Volume 53,791
52-Week Range 8.76 - 22.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics Presents Positive Full Data Set from LANTERN Phase 2 Study of LYR-210 at COSM 2021 Virtual

6 days ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics to Present LANTERN Phase 2 Study Results for LYR 210 in Oral Presentation at COSM 2021 Virtual

2 weeks ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update

1 month ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update

1 month ago - Business Wire

Lyra Therapeutics (LYRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

1 month ago - Zacks Investment Research

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics Announces Appointment of Robert Kern, MD, as Chief Medical Officer

2 months ago - Business Wire

LOS ANGELES, Feb. 1, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lyra Therapeutics, Inc. ...

2 months ago - PRNewsWire

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics Provides Corporate Update and Anticipated Milestones for 2021

2 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $LYRA #LYRA--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Lyra Therapeutics, Inc.

3 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $LYRA #LYRA--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lyra Therapeutics, Inc.

3 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics Announces Positive Topline Results for LANTERN Phase 2 Randomized Controlled Study of LYR-210 for the Treatment of CRS

4 months ago - Business Wire

Lyra is to report top line data of its Phase 2 Trial in December. All indications are the trial should be a success, and they have strong backing from Perceptive Advisors.

4 months ago - Seeking Alpha

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics to Participate in Fireside Chat at the Jefferies Virtual London Healthcare Conference

5 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

5 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics Appoints Nancy L. Snyderman To Its Board of Directors

5 months ago - Business Wire

Two additional presentations highlight supporting data for LYR-210’s clinical program covering key clinical endpoints for CRS and Lyra’s XTreo™ drug release performance

7 months ago - GlobeNewsWire

Three poster presentations to be featured at the 66th Annual Meeting of the American Rhinologic Society Three poster presentations to be featured at the 66th Annual Meeting of the American Rhinologic So...

7 months ago - GlobeNewsWire

Lyra Therapeutics, Inc. (LYRA) CEO Maria Palasis on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

WATERTOWN, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated d...

8 months ago - GlobeNewsWire

WATERTOWN, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated d...

8 months ago - GlobeNewsWire

WATERTOWN, Mass., July 24, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated d...

8 months ago - GlobeNewsWire

Lyra Therapeutics: Advancing An Innovative Solution For Chronic Rhinosinusitis

9 months ago - Seeking Alpha

WATERTOWN, Mass., July 07, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated d...

9 months ago - GlobeNewsWire

Lyra Therapeutics completed its IPO in late-April selling 3.5m shares at a price of $16 - the higher end of expectations - to raise $56m.

10 months ago - Seeking Alpha

WATERTOWN, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated dr...

10 months ago - GlobeNewsWire

Shares of Lyra Therapeutics Inc., a biotech specializing in treatments for ear, nose and throat diseases, soared 32% in their trading debut Friday, after the company's initial public offering priced at ...

11 months ago - Market Watch

When a raging bull market dies and turns into a bear market with a deep recession in less than 45 days, things are not normal.

11 months ago - 24/7 Wall Street

About LYRA

Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase I... [Read more...]

Industry
Biotechnology
IPO Date
May 1, 2020
Stock Exchange
NASDAQ
Ticker Symbol
LYRA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for LYRA stock is "Strong Buy." The 12-month stock price forecast is 26.00, which is an increase of 148.33% from the latest price.

Price Target
$26.00
(148.33% upside)
Analyst Consensus: Strong Buy